GLUCOPHAGE
What it isBiguanide that suppresses hepatic gluconeogenesis and improves insulin sensitivity; first-line for type 2 diabetes.
Why this oneWeight-neutral to weight-losing, causes no hypoglycemia as monotherapy, and carries the longest safety record of any oral agent.
What limits itRenally cleared: avoid below eGFR 30 and hold around iodinated contrast. GI intolerance is the usual reason it fails; long-term use depletes B12.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Type 2 diabetes mellitus | Adults | 500 mg BID or 850 mg QD (with meals) | Titrate to glycemic control | 2550 mg/day divided |
| Type 2 diabetes mellitus | Pediatric 10–16 yr | 500 mg BID (with meals) | Titrate to glycemic control | 2000 mg/day divided BID |
Titration Increase by 500 mg weekly or 850 mg every 2 weeks
Renal Contraindicated if eGFR <30; do not initiate if eGFR 30–45; reassess if eGFR falls <45; check eGFR before and ≥annually
Hepatic Avoid use in hepatic impairment (lactic acidosis risk)
Pregnancy Limited data insufficient to establish risk; published studies show no clear association with birth defects or miscarriage
Lactation Present in human milk; insufficient data on effects on infant or milk production
⚠ BOXED WARNING
Cost, est. cash$5–$150/month
Generic entry2002
Legacy pregnancy categoryB
Defining liabilityGI intolerance and vitamin B12 deficiency; severe renal/hypoxic illness can precipitate lactic acidosis.

Open Metformin in the interactive console ↗

